Michael Birrer on Predicting Outcomes in Ovarian Cancer
Michael Birrer, MD, PhD, Harvard Medical School, discusses what he hopes to discover as factors that influence long-term survival in patients and survivors with ovarian cancer.
Michael Birrer Discusses Personalization of Ovarian Cancer Care
Michael Birrer, MD, PhD, Harvard Medical School, discusses the importance of personalized care for ovarian cancer.
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML